|Day Low/High||34.72 / 35.45|
|52 Wk Low/High||30.33 / 47.82|
Jim Cramer takes a closer look at Dropbox, Teva Pharmaceuticals, Salesforce, Linde, iQiyi and more.
YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Mylan NV has taken over the #180 spot from TechnipFMC plc , according to ETF Channel. Below is a chart of Mylan NV versus TechnipFMC plc plotting their respective rank within the S&P 500 over time (MYL plotted in blue; FTI plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
Shares of generic drugmaker Mylan soar after adjusted earnings top analysts' forecasts.
HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2018 /PRNewswire/ -- Mylan N.
U.S. stock futures are lower on Monday, as stronger-than-expected U.S. jobs data reignites bets on faster Federal Reserve rate hikes and as investors look ahead to the midterm elections on Tuesday; Amazon reportedly has held advanced talks about establishing its second headquarters in Crystal City, Virginia; 'Bohemian Rhapsody' makes $50 million in its opening weekend.
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 /PRNewswire/ -- Mylan N.
- Mylan's Medroxyprogesterone Acetate Injection is indicated for the prevention of pregnancy-
HERTFORDSHIRE, England and PITTSBURGH, Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.
Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid
Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
HERTFORDSHIRE, England and PITTSBURGH and SYDNEY, Sept. 24, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Sept. 21, 2018 /PRNewswire/ -- Mylan N.
- Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis -
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, Sept. 20, 2018 /PRNewswire/ -- Mylan N.
Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®)
- Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate -
Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD
The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.
- Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability -
Stocks ended mixed on Wednesday as a push from strong corporate earnings is muted by continued trade tensions between the U.S. and China.
The drugmaker 's board said the U.S. public markets 'continue to underappreciate and undervalue' the company's diversified business.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.